Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Course of the trial.

From: Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: A randomized, double-blind, placebo-controlled study

  IFN gamma Placebo
Randomized patients 18 14
Treatment interruptions 2 (11.1%) 4 (28.6%)
   Voluntary abandoners 2 (11.1%) 2 (14.3%)
   Deaths 0 2 (14.3%)
Completed 6 months of treatment 16 (88.9%) 10 (71.4%)
Follow-up withdrawals 3 (16.7%) 2 (14.3%)
   Voluntary abandoners 1 (5.5%) 0
   Deaths 2 (11.1%) 2 (14.3%)
Completed 12 months of follow-up 13 (72.2%) 8 (57.1%)
Total deaths 2 (11.1%) 5* (35.7%)
  1. * One of the voluntary abandoners in this group died